TY - JOUR
T1 - Treatment of Ph+ chronic myeloid leukemia by gamma interferon
AU - Russo, Domenico
AU - Fanin, Renato
AU - Zuffa, Eliana
AU - Gallizia, Cristiana
AU - Michieli, Maria Grazia
AU - Damiani, Daniela
AU - Testoni, Nicoletta
AU - Pecile, Vanna
AU - Visani, Giuseppe
AU - Colombini, Roberto
AU - Tosi, Patrizia
AU - Baccarani, Michele
AU - Tura, Sante
PY - 1989/7
Y1 - 1989/7
N2 - The clinical, hematologic and cytogenetic effects of human recombinant gamma interferon (IFN) were investigated in 14 patients with Ph+ chronic myeloid leukemia (CML). Gamma-IFN was given at a daily dosage of 0.50 mg (=10×106 U)/m2 from the 3rd week of treatment on, but the dosage had to be reduced to 0.25 mg/m2 in 10 cases and to 0.35 mg/m2 in 2 cases, because of the severity and persistence of side effects (mainly fever, fatigue, headache and pain). Only 2 patients tolerated the full dosage. The overall response rate was 64% (1 complete and 8 partial hematologic responses). Only patients in stable chronic phase responded. Two out of two patients in unstable chronic phase and two out of two patients in accelerated phase failed to respond. Eight out of nine responding patients remained in remission throughout the duration of treatment (30 to 35 weeks). No karyotypic conversion was detected. These data show that gamma IFN alone is effective in Ph+ CML, but that side effects can limit substantially the dosage and duration of treatment.
AB - The clinical, hematologic and cytogenetic effects of human recombinant gamma interferon (IFN) were investigated in 14 patients with Ph+ chronic myeloid leukemia (CML). Gamma-IFN was given at a daily dosage of 0.50 mg (=10×106 U)/m2 from the 3rd week of treatment on, but the dosage had to be reduced to 0.25 mg/m2 in 10 cases and to 0.35 mg/m2 in 2 cases, because of the severity and persistence of side effects (mainly fever, fatigue, headache and pain). Only 2 patients tolerated the full dosage. The overall response rate was 64% (1 complete and 8 partial hematologic responses). Only patients in stable chronic phase responded. Two out of two patients in unstable chronic phase and two out of two patients in accelerated phase failed to respond. Eight out of nine responding patients remained in remission throughout the duration of treatment (30 to 35 weeks). No karyotypic conversion was detected. These data show that gamma IFN alone is effective in Ph+ CML, but that side effects can limit substantially the dosage and duration of treatment.
KW - Chronic myeloid leukemia
KW - Interferon
UR - http://www.scopus.com/inward/record.url?scp=0024390376&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024390376&partnerID=8YFLogxK
U2 - 10.1007/BF00320241
DO - 10.1007/BF00320241
M3 - Article
C2 - 2502210
AN - SCOPUS:0024390376
VL - 59
SP - 15
EP - 20
JO - Revue d'hématologie
JF - Revue d'hématologie
SN - 0939-5555
IS - 1
ER -